Pipeline
Program/TargetProg/Tgt | IndicationsInds | DiscoveryDiscov | PreclinicalPreclin | ClinicalClin | Current StatusStatus | |
|---|---|---|---|---|---|---|
Breast Cancer & Solid Tumors | ||||||
Breast Cancer & Solid Tumors | Phase 1 enrolling | |||||
OKI-219 is being investigated in the PIKture-01 clinical trial. PIKture-01 is a First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants with Advanced Solid Tumors and in Combination with Endocrine Therapy or HER2-Targeted Therapy in Participants with Advanced Breast Cancer. Additional information about PIKture-01 may be found at www.ClinicalTrials.gov, using Identifier NCT06239467 | ||||||
OKI-TBD | ||||||
Solid Tumors & Breast Cancer | ||||||
OKI-TBD PI3KαPAN mutant selective inhibitor | Solid Tumors & Breast Cancer | Candidate selection | ||||
OKI-TBD | ||||||
Solid Tumors & Breast Cancer | ||||||
OKI-TBD PI3Kα E542K, E545K mutant selective inhibitor | Solid Tumors & Breast Cancer | Active discovery | ||||